Last updated on June 2020

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies


Brief description of study

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2752 in patients with relapsed/refractory solid tumor malignancies or lymphoma.

Detailed Study Description

This is a Phase 1, open-label, multicenter, dose escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in patients with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study consists of 2 dose escalation and dose confirmation parts (Arms A and B) followed by Dose Expansion parts in select indications.

Clinical Study Identifier: NCT03739931

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.